Serum FGF21 levels in adult m.3243A>G carriers: Clinical implications
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To determine the value of fibroblast growth factor 21 (FGF21), a recently discovered biomarker for mitochondrial disease, in predicting clinical disease severity and disease progression in adult carriers of the m.3243A>G mutation. METHODS: In the context of a national inventory, the heteroplasmy levels of the m.3243A>G mutation were measured in leukocytes and urinary epithelial cells. The Newcastle Mitochondrial Disease Adult Scale score was determined and blood was drawn for measuring FGF21 concentration. Twenty-five of the included initial patients studied were then selected randomly for a follow-up study. RESULTS: This prognostic study included 99 adult carriers of the m.3243A>G mutation. Our analysis revealed a moderate, significant correlation between FGF21 concentration and disease severity (r = 0.49; p = <0.001). No significant correlations were found between disease severity and the heteroplasmy percentage determined in urinary epithelial cells or the heteroplasmy percentage determined in leukocytes. Weak but significant correlations were also found between FGF21 concentration and the severity of the myopathy (r = 0.38; p = <0.001) and between the concentration of FGF21 and the severity of the encephalopathy (r = 0.30; p = <0.001). Repeated measurements following 25 subjects for 2 years revealed no significant correlation between FGF21 concentration and disease progression. CONCLUSIONS: Measuring FGF21 concentration had little added value in monitoring and predicting the disease course in this specific patient group.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gälman, C., Lundåsen, T., Kharitonenkov, A., Bina, H. A., Eriksson, M., Hafström, I., Dahlin, M., Åmark, P., Angelin, B., & Rudling, M. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.06.014 · Cited by 512
Suomalainen, A., Elo, J. M., Pietiläinen, K. H., Hakonen, A. H., Sevastianova, K., Korpela, M., Isohanni, P., Marjavaara, S. K., Tyni, T., Kiuru-Enari, S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70155-7 · Cited by 427 · cited 2×
“Measuring the concentration of FGF21, a relatively new diagnostic biomarker, was recently reported to be indicative of clinical severity and disease progression in a heterogeneous cohort of patients with mitochondrial disease.(6) To investigate further the potential prognostic value of this new mitochondrial biomarker…”
BackgroundSelf-citationDecrease of 3243 A–>G mtDNA mutation from blood in MELAS syndrome: a longitudinal study
Rahman, S., Poulton, J., Marchington, D., & Suomalainen, A. (2001) · The American Journal of Human Genetics · doi:10.1086/316930 · Cited by 237
Fibroblast Growth Factor-21 Is Induced in Human Skeletal Muscles by Hyperinsulinemia
Hojman, P., Pedersen, M., Nielsen, A. R., Krogh-Madsen, R., Yfanti, C., Åkerstrom, T., Nielsen, S., & Pedersen, B. K. (2009) · Diabetes · doi:10.2337/db09-0713 · Cited by 198
Cited by
Understanding the Physiology of FGF21
Fisher, F. M., & Maratos-Flier, E. (2016) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021115-105339 · Cited by 912
FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders
Lehtonen, J. M., Forsström, S., Bottani, E., Viscomi, C., Baris, O. R., Isoniemi, H., Höckerstedt, K., Österlund, P., Hurme, M., Jylhävä, J., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003374 · Cited by 220
Self-citationMitochondrial disease in adults: what's old and what's new?
Chinnery, P. F. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505079 · Cited by 133
Metadata
- Authors
- Koene, S., de Laat, P., van Tienoven, D. H., Vriens, D., Brandt, A. M., Sweep, F. C. G. J., Rodenburg, R. J. T., Donders, A. R. T., Janssen, M. C. H., & Smeitink, J. A. M.
- Venue
- Neurology
- Published
- 2014-07-08
- Volume
- 83
- Issue
- 2
- Pages
- 125-133
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2142847844
- Cited by
- 39
- References
- 4
- FWCI
- 1.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum FGF21 levels in adult m.3243A>G carriers: Clinical implications. https://app.cochat.ai/papers/10.1212/wnl.0000000000000578
- The paper
- Koene, S., de Laat, P., van Tienoven, D. H., Vriens, D., Brandt, A. M., Sweep, F. C. G. J., Rodenburg, R. J. T., Donders, A. R. T., Janssen, M. C. H., & Smeitink, J. A. M. (2014). Serum FGF21 levels in adult m.3243A>G carriers: Clinical implications. Neurology. https://doi.org/10.1212/wnl.0000000000000578
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.